BioAtla, Inc. Q1 2025 10-Q Filing
Ticker: BCAB · Form: 10-Q · Filed: May 6, 2025 · CIK: 1826892
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
BioAtla's Q1 2025 10-Q shows cash, R&D spend, and warrant details.
AI Summary
BioAtla, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial position and operational activities, including details on cash, research and development expenses, and general administrative costs for the first quarter of 2025. Specific figures for assets like laboratory equipment and liabilities such as warrants are also detailed.
Why It Matters
This filing provides investors with an update on BioAtla's financial health and operational spending, crucial for understanding the company's progress in the biopharmaceutical sector.
Risk Assessment
Risk Level: medium — As a biopharmaceutical company, BioAtla faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the financial snapshot date.)
- 2025-05-06 — Filing Date (Shows when the report was submitted to the SEC.)
Key Players & Entities
- BioAtla, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of reporting period
- 20250506 (date) — Filing date
- SAN DIEGO, CA (location) — Company headquarters and mailing address
FAQ
What were BioAtla's research and development expenses for the first quarter of 2025?
The filing indicates research and development expenses were incurred between 2025-01-01 and 2025-03-31.
What is the company's fiscal year end?
BioAtla, Inc.'s fiscal year ends on 1231.
What is the company's primary business classification?
The company is classified under 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]'.
When was BioAtla, Inc. incorporated?
The company was incorporated in DE.
What is the company's SEC file number?
The SEC file number for BioAtla, Inc. is 001-39787.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 6, 2025 regarding BioAtla, Inc. (BCAB).